AnalystBook Research · Company Intelligence

Connect Biopharma Holdings Ltd

CNTBNasdaq

Built from Connect Biopharma Holdings Ltd's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Connect Biopharma Holdings Ltd: Revenue declined 99.8% to $64K from $26.03M. Net loss widened to $55.48M from $15.63M. Free cash flow outflow widened to $51.64M from $24.36M. Operating margin contracted 9065439 bps to -90740.63%. Connect Biopharma Holdings Ltd's annual comparison also shows the manipulation screen is flagged and should be investigated as a warning rather than treated as proof; the balance-sheet screen falls in the distress range and requires business-model context; the earnings-quality screen is distress.

The read at a glance✓ Audited against SEC data
  • GrowthRevenue declined 99.8% to $64K from $26.03MWatch
  • ProfitabilityNet loss widened to $55.48M from $15.63MWatch
  • Cash flowFree cash flow outflow widened to $51.64M from $24.36MWatch
  • MarginsOperating margin contracted 9065439 bps to -90740.63%Watch
  • AccountingFlagged statistical warning; not proofWatch
  • Insiders1 purchase and 0 salesOK

Business

Significant Unmet Need and Market Opportunity in Asthma Asthma is a chronic inflammatory disease that affects the airways in the lungs and makes it difficult to breathe.

Where the revenue comes from

Fiscal 2025, as Connect Biopharma Holdings Ltd reports it. History and quarterly detail are in the app.

  • Clinical Trial Reports$100K

Leadership changes

From Connect Biopharma Holdings Ltd's own filings, the day they're filed.

  • James A. Schoeneck · Chief Executive Officer · appointment

Latest filings

  • 8-K · Company announcement2026-08-12
  • 10-Q · Quarterly report2026-08-12
  • 8-K · Company announcement2026-05-12
  • 10-Q · Quarterly report2026-05-12
  • 8-K · Company announcement2026-04-23
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Connect Biopharma Holdings Ltd, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.